GSK Exercises Option to License ChemoCentryx's CCR1 Inhibitor, CCX354, for the …
5, 2012 /PRNewswire via COMTEX/ — ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, …
See all stories on this topic »